Headlines about Vical (NASDAQ:VICL) have been trending somewhat positive on Friday, according to Accern. Accern ranks the sentiment of press coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Vical earned a coverage optimism score of 0.21 on Accern’s scale. Accern also gave media stories about the biotechnology company an impact score of 45.7516179924963 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

Several analysts recently issued reports on VICL shares. HC Wainwright restated a “buy” rating and set a $6.00 target price on shares of Vical in a research report on Tuesday, November 21st. Zacks Investment Research raised shares of Vical from a “sell” rating to a “hold” rating in a report on Saturday, December 2nd. Finally, ValuEngine downgraded shares of Vical from a “sell” rating to a “strong sell” rating in a report on Friday, September 1st. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus price target of $7.50.

Shares of Vical (NASDAQ VICL) traded down $0.06 during trading hours on Friday, reaching $1.77. 55,700 shares of the company’s stock traded hands, compared to its average volume of 173,343. Vical has a twelve month low of $1.66 and a twelve month high of $3.70.

Vical (NASDAQ:VICL) last issued its quarterly earnings results on Monday, October 23rd. The biotechnology company reported ($0.27) earnings per share for the quarter, missing the consensus estimate of ($0.25) by ($0.02). Vical had a negative net margin of 92.13% and a negative return on equity of 29.06%. The firm had revenue of $3.24 million for the quarter, compared to analysts’ expectations of $3.60 million. equities research analysts forecast that Vical will post -1 EPS for the current fiscal year.

In other news, Director Robert C. Merton purchased 85,700 shares of the stock in a transaction on Friday, November 10th. The shares were acquired at an average price of $1.75 per share, with a total value of $149,975.00. Following the completion of the acquisition, the director now directly owns 95,451 shares of the company’s stock, valued at $167,039.25. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink. 5.98% of the stock is owned by insiders.

TRADEMARK VIOLATION NOTICE: “Vical (VICL) Receives News Sentiment Score of 0.21” was originally published by Watch List News and is the property of of Watch List News. If you are viewing this story on another publication, it was copied illegally and republished in violation of US & international trademark and copyright legislation. The original version of this story can be viewed at https://www.watchlistnews.com/vical-vicl-receives-news-sentiment-score-of-0-21/1766183.html.

Vical Company Profile

Insider Buying and Selling by Quarter for Vical (NASDAQ:VICL)

Receive News & Ratings for Vical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vical and related companies with MarketBeat.com's FREE daily email newsletter.